EBO: Healthcare Distributor - The $360 Million Question
EBO: Healthcare Distributor - The $360 Million Question
In a Nutshell
Executive Summary
In a Nutshell
EBOS Group is Australasia's dominant pharmaceutical and healthcare distributor, delivering medicines to pharmacies, hospitals and aged-care facilities while also owning a growing pet food and veterinary business. At A$20.08 against a fair value of A$35.57, the stock is undervalued by 77%. The key driver is a margin trough caused by a once-in-a-generation distribution centre rebuild — now largely complete — and a freshly signed government funding agreement that begins lifting revenue from July 2026.
Investor Profiles
| Profile | Rating | Rationale |
|---|---|---|
| Income | ★★★☆☆ | The dividend yields 5.1% at current prices, with an 82% payout ratio that is well-supported by recurring cash flows. DPS grows from A$1.09 in FY26 to A$1.40 in FY28 as earnings recover. This is adequate but not exceptional — the NZD reporting currency introduces currency noise for AUD-focused income investors. |
| Value | ★★★★☆ | At 9.8× trailing EV/EBITDA against an ANZ healthcare peer range of 12–16×, EBOS carries a meaningful multiple discount with a specific, time-bound reason for it. The 77% gap to fair value is not built on heroic assumptions — revenue grows below GDP-plus-2% and terminal margins sit below the historical average. This is a good fit for value investors willing to wait 12–24 months for the re-rating. |
| Growth | ★★☆☆☆ | Revenue grows at 7–9% over the next three years, driven by GLP-1 prescription volumes, a new hospital contract win and the SVS veterinary acquisition — not share gains. EPS accelerates from A$1.33 in FY26 to A$1.73 in FY28 as the cost drag reverses. This is moderate, not compelling, growth — not ideal for investors seeking double-digit top-line expansion. |
| Quality | ★★★☆☆ | ROIC sits at 12.9% and climbs modestly to 13.5% by FY28, reflecting the goodwill-heavy balance sheet from acquisitions. The competitive moat is wide — 75–80% wholesale market share underpinned by a A$4.2 billion government contract — but capital efficiency is only medium-rated. Quality investors will appreciate the moat but note that leverage at 2.2× net debt/EBITDA leaves limited margin for error. |
| Thematic | ★★★★☆ | EBOS sits at the intersection of two durable structural trends: the GLP-1/obesity medicine wave flowing through Australian pharmacies, and the humanisation of pets driving vet pharmaceutical demand. PBS prescription volumes are growing at 4–6% purely from demographics and new medicine listings. This is a strong fit for investors building exposure to the ANZ healthcare infrastructure theme without taking drug-discovery risk. |
Best fit: Value investors with a 12–24 month horizon. EBOS is a high-quality, regulated business whose margin trough is fully explained by a capital programme now entering its final phase. The 77% discount to fair value reflects market scepticism about the recovery timeline and a structural discount from the NZX/ASX dual-listing — not deteriorating fundamentals. Investors who can hold through the noise and wait for the August 2026 results to confirm the margin inflection are best positioned to capture the re-rating.
Executive Summary
EBOS Group delivers roughly three in every four prescription medicines dispensed in Australia and New Zealand. It earns a small margin on enormous volume — distributing pharmaceuticals, medical devices and consumer health products to pharmacies, hospitals and aged-care homes — while a separate Animal Care division manufactures and distributes pet food brands and veterinary products.
The most recent half-year result told a tale of two dynamics. Revenue grew 13% to A$6.8 billion as new hospital and aged-care contracts contributed and the veterinary acquisition scaled up. Yet margins remained compressed, because EBOS has been running two parallel distribution networks while completing a A$360 million national DC rebuild — a transition programme that deliberately depressed earnings while protecting service reliability.
The investment case rests on three observable, time-bound events. Six of eight new distribution centres are now operational and on-budget, meaning transition costs reverse mechanically into FY27. A freshly signed five-year government Community Service Obligation agreement adds a contractually locked revenue uplift from July 2026. And the GLP-1 obesity medicine wave is structurally growing the volume of high-value prescriptions flowing through EBOS's network each month. None of these require management heroics — they are already contracted or physically complete.
At A$20.08 versus a fair value of A$35.57, the stock is undervalued by 77%.
Results & Outlook
What happened?
The first half of FY26 delivered A$6.8 billion in revenue — up 13% — driven by new contract wins, the full contribution of the SVS veterinary acquisition and accelerating GLP-1 script volumes. Underlying EBITDA margins remained below historical norms as transition costs from the DC rebuild peaked. Management reaffirmed full-year EBITDA guidance of A$615–635 million, consistent with our A$625 million estimate.
| Metric | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|
| Revenue (A$m) | 12,267 | 13,400 | 14,460 | 15,473 |
| EBITDA (A$m) | 585 | 625 | 651 | 727 |
| EBITDA Margin | 4.8% | 4.7% | 4.5% | 4.7% |
| EPS (A$) | 1.05 | 1.33 | 1.42 | 1.73 |
| DPS (A$) | 1.02 | 1.09 | 1.17 | 1.40 |
| Free Cash Flow (A$m) | 267 | 226 | 326 | 385 |
What's next?
Three catalysts sit on a known schedule. The DC rebuild completes in FY26, mechanically reversing A$20–30 million in annual transition costs that have been suppressing Healthcare margins. The new Community Service Obligation agreement activates in July 2026, adding a contractually locked funding uplift that has not been quantified publicly but is embedded in management's guidance. Capital expenditure falls from A$146 million in FY25 toward A$93 million in FY28 as the build programme winds down, which directly converts to free cash flow growth.
The April 2026 Investor Day is the near-term inflection point. New CEO Adam Hall will present his first strategic framework — a credibility event that the market is watching closely given the leadership change. The August 2026 full-year results will provide the first clean read on whether DC cost reversal is tracking as expected. If Healthcare operating costs as a proportion of revenue fall below 7.5% in that result, the structural thesis is confirmed.
Valuation & Risks
| Metric | Value |
|---|---|
| Fair Value | A$35.57 |
| Current Price | A$20.08 |
| Upside to Fair Value | +77% |
| Bear Case | A$30.10 (+50%) |
| Bull Case | A$46.20 (+130%) |
| EV/EBITDA (current) | 9.8× FY25 |
| EV/EBITDA (peer median) | 12–13× |
The fair value of A$35.57 is derived from a probability-weighted DCF (55% weight), trading multiples (35%) and transaction comparables (10%), using a 7.5% WACC and 3.0% terminal growth. The single most important variable is the terminal EBITDA margin — each 100 basis-point movement shifts fair value by roughly A$11.50 per share.
The biggest risk is not operational — it is structural. EBOS's NZX/ASX dual-listing, NZD reporting currency and limited Australian institutional coverage appear to impose a persistent discount that our valuation framework cannot fully quantify. The market is implying a required return of roughly 10.5% against our CAPM-derived 7.5% — a 300 basis-point gap that accounts for almost the entire A$15 difference between current price and fair value. If that discount is permanent rather than temporary, the stock may be fairly priced as far as the ASX market is concerned regardless of operational delivery. The April 2026 Investor Day is the first opportunity to assess whether new CEO Adam Hall can broaden the investor base and compress that structural gap.